Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study

Authors: Johannes Baur, Tjark-Ole Büntemeyer, Felix Megerle, Timo Deutschbein, Christine Spitzweg, Marcus Quinkler, Peter Nawroth, Matthias Kroiss, Christoph-Thomas Germer, Martin Fassnacht, Ulrich Steger, on behalf of the German Adrenocortical Carcinoma Study Group

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Metastatic Adrenocortical Carcinoma (ACC) is a rare malignancy with a poor 5-year-survival rate (<15%). A surgical approach is recommended in selected patients if complete resection of distant metastasis can be achieved. To date there are only limited data on the outcome after surgical resection of hepatic metastases of ACC.

Methods

A retrospective analysis of the German Adrenocortical Carcinoma Registry was conducted. Patients with liver metastases of ACC but without extrahepatic metastases or incomplete tumour resection were included.

Results

Seventy-seven patients fulfilled these criteria. Forty-three patients underwent resection of liver metastases of ACC. Complete tumour resection (R0) could be achieved in 30 (69.8%). Median overall survival after liver resection was 76.1 months in comparison to 10.1 months in the 34 remaining patients with unresected liver metastases (p < 0.001). However, disease free survival after liver resection was only 9.1 months. Neither resection status (R0/R1) nor extent of liver resection were significant predictive factors for overall survival. Patients with a time interval to the first metastasis/recurrence (TTFR) of greater than 12 months or solitary liver metastases showed significantly prolonged survival.

Conclusions

Liver resection in the case of ACC liver metastases can achieve long term survival with a median overall survival of more than 5 years, but disease free survival is short despite metastasectomy. Time to recurrence and single versus multiple metastases are predictive factors for the outcome.
Literature
1.
go back to reference Kerkhofs TMA, Verhoeven RHA, van der Zwan JM, Dieleman J, Kerstens MN, Links TP, van de Poll-Franse LV, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579–86.CrossRefPubMed Kerkhofs TMA, Verhoeven RHA, van der Zwan JM, Dieleman J, Kerstens MN, Links TP, van de Poll-Franse LV, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579–86.CrossRefPubMed
2.
go back to reference Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551–64.CrossRefPubMed Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:4551–64.CrossRefPubMed
3.
go back to reference Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282–326.CrossRefPubMed Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282–326.CrossRefPubMed
4.
go back to reference Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes. 2017;24:208–14.CrossRefPubMed Varghese J, Habra MA. Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes. 2017;24:208–14.CrossRefPubMed
5.
go back to reference Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243–50.CrossRefPubMed Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243–50.CrossRefPubMed
6.
go back to reference Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363–9.CrossRefPubMed Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363–9.CrossRefPubMed
7.
go back to reference Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii131–8.CrossRefPubMed Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii131–8.CrossRefPubMed
8.
go back to reference Gaujoux S, Mihai R. European Society of Endocrine Surgeons (ESES) and European network for the study of adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg. 2017;104:358–76.CrossRefPubMed Gaujoux S, Mihai R. European Society of Endocrine Surgeons (ESES) and European network for the study of adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg. 2017;104:358–76.CrossRefPubMed
9.
go back to reference Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:181–91.CrossRefPubMed Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:181–91.CrossRefPubMed
10.
go back to reference Simon G, Pattou F, Mirallie E, Lifante JC, Nomine C, Arnault V, et al. Surgery for recurrent adrenocortical carcinoma: a multicenter retrospective study. Surgery. 2017;161:249–56.CrossRefPubMed Simon G, Pattou F, Mirallie E, Lifante JC, Nomine C, Arnault V, et al. Surgery for recurrent adrenocortical carcinoma: a multicenter retrospective study. Surgery. 2017;161:249–56.CrossRefPubMed
11.
go back to reference Adam R, Gramont A de, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225–1239. Adam R, Gramont A de, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225–1239.
12.
go back to reference Fitzgerald TL, Brinkley J, Banks S, Vohra N, Englert ZP, Zervos EE. The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbeck's Arch Surg. 2014;399:989–1000.CrossRef Fitzgerald TL, Brinkley J, Banks S, Vohra N, Englert ZP, Zervos EE. The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbeck's Arch Surg. 2014;399:989–1000.CrossRef
13.
go back to reference Koschker A-C, Fassnacht M, Hahner S, Weismann D, Allolio B. Adrenocortical carcinoma -- improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes. 2006;114:45–51.CrossRefPubMed Koschker A-C, Fassnacht M, Hahner S, Weismann D, Allolio B. Adrenocortical carcinoma -- improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes. 2006;114:45–51.CrossRefPubMed
14.
go back to reference Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524–35.CrossRefPubMedPubMedCentral Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524–35.CrossRefPubMedPubMedCentral
15.
go back to reference Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011;18:1972–9.CrossRefPubMedPubMedCentral Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011;18:1972–9.CrossRefPubMedPubMedCentral
16.
go back to reference Bauditz J, Quinkler M, Wermke W. Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature. Exp Clin Endocrinol Diabetes. 2009;117:316–9.CrossRefPubMed Bauditz J, Quinkler M, Wermke W. Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature. Exp Clin Endocrinol Diabetes. 2009;117:316–9.CrossRefPubMed
17.
go back to reference Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D'Angelica M, Harrison LE, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg. 2005;241:269–76.CrossRefPubMedPubMedCentral Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D'Angelica M, Harrison LE, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg. 2005;241:269–76.CrossRefPubMedPubMedCentral
18.
go back to reference Gaujoux S, Al-Ahmadie H, Allen PJ, Gonen M, Shia J, D'Angelica M, et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol. 2012;19:2643–51.CrossRefPubMed Gaujoux S, Al-Ahmadie H, Allen PJ, Gonen M, Shia J, D'Angelica M, et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol. 2012;19:2643–51.CrossRefPubMed
19.
go back to reference Haas RJ de, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008;248:626–637. Haas RJ de, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008;248:626–637.
20.
go back to reference Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011;2:363–71.CrossRefPubMed Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011;2:363–71.CrossRefPubMed
21.
go back to reference Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.CrossRefPubMed Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.CrossRefPubMed
22.
go back to reference Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second−/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17:445–53.CrossRefPubMed Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second−/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17:445–53.CrossRefPubMed
23.
go back to reference Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162:349–56.CrossRefPubMed Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162:349–56.CrossRefPubMed
24.
go back to reference Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97:3495–503.CrossRefPubMed Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97:3495–503.CrossRefPubMed
25.
go back to reference Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166:451–8.CrossRefPubMed Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166:451–8.CrossRefPubMed
26.
go back to reference Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426–35.CrossRefPubMed Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426–35.CrossRefPubMed
27.
go back to reference Kroiss M, Deutschbein T, Schlotelburg W, Ronchi CL, Neu B, Muller H-H, et al. Salvage treatment of Adrenocortical carcinoma with Trofosfamide. Horm Cancer. 2016;7:211–8.CrossRefPubMed Kroiss M, Deutschbein T, Schlotelburg W, Ronchi CL, Neu B, Muller H-H, et al. Salvage treatment of Adrenocortical carcinoma with Trofosfamide. Horm Cancer. 2016;7:211–8.CrossRefPubMed
28.
go back to reference Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.CrossRefPubMed Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–80.CrossRefPubMed
29.
go back to reference Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, et al. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015;22:146–51.CrossRefPubMed Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, et al. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015;22:146–51.CrossRefPubMed
Metadata
Title
Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study
Authors
Johannes Baur
Tjark-Ole Büntemeyer
Felix Megerle
Timo Deutschbein
Christine Spitzweg
Marcus Quinkler
Peter Nawroth
Matthias Kroiss
Christoph-Thomas Germer
Martin Fassnacht
Ulrich Steger
on behalf of the German Adrenocortical Carcinoma Study Group
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3506-z

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine